← back to search

Nabil Ahmed

Houston Methodist · US
Area of research
Oncology · Immunology
Research interest
Research interests include CAR-T cell therapy research, Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, and Virus-based gene therapy research.
h-index
40
citations
11,807
works
276
NIH funding
—
primary concept
Medicine
email
nahmed@bcm.edu

Recent publications

Immunotherapy approaches for the treatment of relapsed or progressive medulloblastoma.
2026cited by 0position: contributordoi
Molecular dynamics at immune synapse lipid rafts influence the cytolytic behavior of CAR T cells.
2025cited by 10position: contributordoi
A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function.
2025cited by 2position: contributordoi
Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas.
2025cited by 1position: contributordoi
Supplementary Figure 5 from A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function
2025cited by 0position: contributordoi
Figure 6 from A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function
2025cited by 0position: contributordoi
Data from Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas
2025cited by 0position: contributordoi
Supplementary Figure 1 from A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function
2025cited by 0position: contributordoi
Figure 3 from A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function
2025cited by 0position: contributordoi
Supplementary Figure 4 from Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas
2025cited by 0position: contributordoi
Figure 5 from A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function
2025cited by 0position: contributordoi
Supplementary Table 2 from Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas
2025cited by 0position: contributordoi
Supplementary Figure 8 from A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function
2025cited by 0position: contributordoi
Figure 4 from A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function
2025cited by 0position: contributordoi
Supplementary Figure 5 from Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas
2025cited by 0position: contributordoi
Supplementary Figure 3 from A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function
2025cited by 0position: contributordoi
Supplementary Figure 7 from A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function
2025cited by 0position: contributordoi
Supplementary Figure 2 from Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas
2025cited by 0position: contributordoi
Supplementary Figure 6 from A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function
2025cited by 0position: contributordoi
Supplementary Figure 3 from A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function
2025cited by 0position: contributordoi
Data from A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function
2025cited by 0position: contributordoi
Figure 7 from A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function
2025cited by 0position: contributordoi
Figure 1 from A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function
2025cited by 0position: contributordoi
Supplementary Figure 2 from A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function
2025cited by 0position: contributordoi
Supplementary Figure 11 from A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function
2025cited by 0position: contributordoi
Supplementary Figure 6 from Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas
2025cited by 0position: contributordoi
Supplementary Table 1 from Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas
2025cited by 0position: contributordoi
Supplementary Figure 10 from A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function
2025cited by 0position: contributordoi
Figure 2 from A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function
2025cited by 0position: contributordoi
Supplementary Figure 6 from A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function
2025cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

— · 20 papers (2020–2026)— · 16 papers (2020–2025)— · 14 papers (2020–2025)Matthew L. Baker · Baylor College of Medicine13 papers (2013–2025)— · 12 papers (2021–2025)Jessica S. Morris · Baylor College of Medicine11 papers (2025–2025)Mohamed F. Sheha · Ain Shams University11 papers (2025–2025)Sybrina S. Kerr · 11 papers (2025–2025)Harrison R. Berger · Houston Methodist11 papers (2025–2025)Ada I. Ozcan · Baylor College of Medicine10 papers (2025–2025)— · 10 papers (2025–2025)Poul H. Sorensen · Ontario Institute for Cancer Research10 papers (2025–2025)— · 10 papers (2025–2025)M. John Hicks · Baylor College of Medicine10 papers (2025–2025)Jason T. Yustein · Emory University10 papers (2025–2025)Mary Kathryn McKenna · Baylor College of Medicine10 papers (2025–2025)Atreyi Dasgupta · Baylor College of Medicine10 papers (2025–2025)Angela M. Major · 10 papers (2025–2025)Jeneffer Mirabal · 10 papers (2025–2025)Ben K. Seon · Roswell Park Comprehensive Cancer Center10 papers (2025–2025)